Glaukos

Glaukos Corp. is an ophthalmic medical technology and pharmaceutical company, which focuses on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. It engages in development and commercialization of therapies across several end markets within ophthalmology. The company was founded by Olav B. Bergheim, Morteza Gharib, and Richard Hill on July 14, 1998 and is headquartered in San Clemente, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Glaukos reports robust Q4 earnings, sets ambitious growth plans for 2023

Glaukos delivered strong financial performance in Q4 2022 and outlined ambitious plans for 2023, focusing on innovation and market expansion. Despite staffing challenges and operating expense growth, the company remains optimistic about its growth prospects. Opportunities in advancing key products and addressing market dynamics position Glaukos for continued success.

Glaukos reports strong Q1 earnings, eyes international market opportunities

Glaukos delivered robust financial results in Q1 2023, showcasing growth in key franchises and advancing its pipeline. The company faces challenges in operational efficiency and market expansion but holds opportunities in international markets and innovative product offerings. Overall, Glaukos remains well-positioned for future growth and success.

Glaukos reports record Q2 sales, eyes international growth opportunities

Glaukos delivered strong Q2 results, with a focus on strategic investments for iDose launch and maintaining growth momentum. Challenges include reimbursement changes and healthcare trend normalization. Opportunities lie in international expansion and new product launches.

Glaukos reports robust Q3 sales, eyes early glaucoma intervention

Glaukos shows strong performance with sales growth and strategic developments.
Facing challenges in market share and FDA concerns but seizing growth opportunities.
Confidence in ongoing projects and commitment to advancing glaucoma therapies.
Strategic focus on innovation and market expansion in the glaucoma sector.

Glaukos achieves record sales, focuses on innovation and market growth

Glaukos delivered strong financial performance, with a focus on innovation and market leadership in the ophthalmic space.
The company's strategic strengths lie in its product portfolio, market access initiatives, and commitment to driving change in the standard of care.
Challenges include managing physician time allocation, balancing growth strategies, and ensuring successful product launches.
Opportunities for Glaukos include increased adoption of innovative products, pipeline advancements, and continued investment in driving future growth.

Glaukos reports record sales and raises guidance for 2024

Glaukos is on track for strong financial performance with record sales and increased guidance. The company faces challenges with iDose adoption and reimbursement timelines but sees opportunities for growth in various product lines.

Glaukos reports record Q2 sales, raises guidance amid innovation focus

Glaukos delivered strong financial performance in Q2 2024, with record net sales and raised full year guidance, driven by robust sales across key franchises.
The company's focus on innovation, balance sheet strengthening, and market expansion positions it well for future growth and competitive advantage.
While facing regulatory and operational challenges, Glaukos has opportunities to capitalize on market trends, product adoption, and international expansion.
Navigating these challenges and leveraging opportunities will be crucial for Glaukos to sustain growth momentum and enhance shareholder value.

Glaukos reports record Q3 sales, eyes growth through product launches

Glaukos delivered strong financial performance in Q3 2024, with record net sales and raised full year guidance. The company's focus on product innovation, market expansion, and reimbursement strategies positions it well for future growth. While challenges in financial restructuring and market access exist, opportunities in product launches and international expansion offer promising prospects.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Glaukos Corp. is an ophthalmic medical technology and pharmaceutical company, which focuses on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It engages in development and commercialization of therapies across several end markets within ophthalmology. The company was founded by Olav B. Bergheim, Morteza Gharib, and Richard Hill on July 14, 1998 and is headquartered in Aliso Viejo, CA.

Centers for Medicare and Medicaid Services (CMS) issued its fiscal 2022 proposed physician fee schedule, which included two combined Category I cataract plus stent procedure codes. The physicians will use the codes to seek reimbursement utilizing Glaukos Corporation's (NYSE: GKOS) trabecular micro-bypass technologies (iStent, iStent inject, iStent inject W) when used as approved in combination with cataract surgery.

William Blair Downgrades Glaukos After Disappointing CMS Rate; Shares Drop

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today commented on the recently released Centers for Medicare and Medicaid Services (CMS) Calendar Year 2022 Medicare Physician Fee Schedule Proposed Rule. The Proposed Rule was released on July 13, 2021, and updates payment policies, payment rates and other provision

Glaukos Comments on the Centers for Medicare and Medicaid Services 2022 Proposed Physician Fee Schedule

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced the completion of patient enrollment and randomization in its U.S. Food and Drug Administration (FDA) New Drug Application (NDA) Phase 3 clinical trials for the iDose® TR sustained-release travoprost implant. The iDose TR Phase 3 clinical program consi

Glaukos Achieves Pipeline Milestone with Completion of Patient Enrollment in U.S. NDA Phase 3 Clinical Trials for iDose® TR

SEATTLE & BOSTON--(BUSINESS WIRE)--Aurion Biotech launches; Greg Kunst joins as CEO

Greg Kunst Appointed CEO of Aurion Biotech

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that the Therapeutic Goods Administration (TGA) of Australia has granted regulatory approval for the PRESERFLO MicroShunt intended for the reduction of intraocular pressure (IOP) in eyes of patients with primary open-angle glaucoma where IOP remains un

Glaukos Announces Australia's TGA Regulatory Approval for PRESERFLO™ MicroShunt

I covered Glaukos twice last year during what I felt like was a temporary setback due to the COVID-19 pandemic. Since that time, Glaukos shares have rallied substantially as those headwinds started to subside.

An Updated Look At Glaukos

Glaukos (GKOS) reported earnings 30 days ago. What's next for the stock?

Glaukos (GKOS) Down 11.1% Since Last Earnings Report: Can It Rebound?

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to virtually participate in the William Blair 41st Annual Growth Stock Conference on Wednesday, June 2, 2021, at 4:40 p.m. CDT. A live and archived webcast for this event will be available in the Investors section of th

Glaukos Announces Participation in the William Blair 41st Annual Growth Stock Conference

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that it has entered into a new development and commercialization license agreement with Santen Pharmaceutical Co., Ltd. (Santen) for the PRESERFLO™ MicroShunt (development code: DE-128), superseding the previous collaboration and distribution agreement

Glaukos Expands its PRESERFLO™ MicroShunt Relationship with Santen via New License Agreement

Despite reporting first-quarter loss, Glaukos' (GKOS) results reflect rise in revenues.

Glaukos (GKOS) Loses 14.3% Despite Narrower Loss in Q1

Glaukos Corp (GKOS) CEO Tom Burns on Q1 2021 Results - Earnings Call Transcript

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the first quarter ended March 31, 2021. Key highlights include: Net sales growth of 23% to $68.0 million in Q1 2021, compared to $55.3 million in Q1 2020. Glaucoma net sales of $53.7 million and Corneal Health net sales of $14.3 m

Glaukos Corporation Announces First Quarter 2021 Financial Results

Glaukos (NYSE:GKOS) announces its next round of earnings this Wednesday, May 05. Here is Benzinga's look at Glaukos's Q1 earnings report.

Glaukos's Earnings: A Preview

Glaukos (GKOS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Glaukos (GKOS) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that it has published its 2020 Sustainability Report. The report highlights the company's continued commitment and progress on environmental, social and governance (ESG) initiatives. The Sustainability Report can be found on the company's website here.

Glaukos Announces the Release of its 2020 Sustainability Report

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that it has entered into an amended licensing agreement with Intratus, Inc. under which Intratus has granted Glaukos a global exclusive license to research, develop, manufacture and commercialize Intratus' patented, non-invasive drug delivery platform

Glaukos Announces Global Licensing Agreement Amendment with Intratus, Inc. to Include the Treatment of Presbyopia

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release first quarter 2021 financial results after the market close on Wednesday, May 5, 2021. The company's management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PDT (4:30 p.m. EDT) on May 5, 2021. A link to the l

Glaukos Corporation to Release First Quarter 2021 Financial Results after Market Close on May 5

Why Is Glaukos (GKOS) Down 7.1% Since Last Earnings Report?

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced two new patient-centric initiatives in honor of World Glaucoma Week. World Glaucoma Week is an annual global initiative championed by the World Glaucoma Association (WGA) to raise awareness surrounding the risk and prevalence of glaucoma. As a proud sp

Glaukos to Support World Glaucoma Week with Patient Education Campaign and Free Screening Initiatives

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to virtually participate in the Oppenheimer 31st Annual Healthcare Conference on Tuesday, March 16, 2021, at 3:10 p.m. EDT. A live and archived webcast for this event will be available in the Investors section of the Gl

Glaukos Announces Participation in Oppenheimer Healthcare Conference

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced the appointment of Denice Torres and Dr. Leana Wen to its Board of Directors, effective today. With the addition of these two directors, Glaukos' Board of Directors will be comprised of nine directors, eight of whom are independent. “We are delighted a

Glaukos Appoints Denice Torres and Dr. Leana Wen to its Board of Directors

Glaukos' (GKOS) CEO Tom Burns on Q4 2020 Results - Earnings Call Transcript

Glaukos Corp (NYSE: GKOS) has announced topline data from the U.S. Phase 3 trial evaluating its corneal cross-linking iLink therapy to treat keratoconus. Keratoconus is characterized by cone-shaped cornea causing blurred vision and sensitivity to light and glare.

Glaukos' iLink Therapy Meets Primary Endpoint In Late-Stage Vision Disorder Study

Shares of Glaukos (NYSE:GKOS) were flat after-market trading after the company reported Q4 results. Quarterly Results Earnings per share were up 66.67% year over year to ($0.02), which beat the estimate of ($0.29).

Glaukos: Q4 Earnings Insights

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the fourth quarter and full year ended December 31, 2020. Key highlights include: Net sales of $73.2 million in Q4 2020, compared to $65.8 million in Q4 2019. Glaucoma net sales of $58.4 million and Corneal Health net sales of $14

News for Glaukos Stock (GKOS)